Carcinos Healthcare has partnered with US-based C2i Genomics to promote AI cancer.

Karkinos Healthcare, a technology-driven cancer care platform in India, has entered into a strategic partnership with American oncology diagnostic firm C2i Genomics to promote AI-enabled cancer monitoring in the country.

According to a press release, their partnership will extend Minimal Residual Disease (MRD) monitoring across Carkinos ‘network using C2i Genomics’ full-genome analysis platform. MRD means that a small number of cancer cells remain in the patient’s body after treatment.

Carcinos operates a distributed cancer care network model, coordinating healthcare organizations and professionals to provide streamlined access to cancer care. It is presently located in eight states of India and parts of the National Capital Region of India.

Why it matters

Over the past decade, the number of its new cancer cases in India has increased by a fifth, from 18.7 million in 2010 to 23 million in 2019. Cancer deaths have also risen by a quarter to 10 million. According to C2i Genomics, these growing statistics suggest the need for better cancer detection and treatment options for the Indian population.

The diagnostic company C2inform offers MRD tests that detect the amount of traces of recurrent cancer. A blood sample is analyzed using cloud-based software that uses AI to detect recurrence or prevention of cancer “much earlier and at a much lower level” than other technologies on the market.

Karkinos will be conducting C2i MRD tests at his Advanced Center for Cancer Diagnostics and Research in Kochi.

Greater trend

Karkinos C2i has added a growing list of Genomics partners who have adopted its MRD monitoring platform, including Singapore-based biotech company NovogeneAIT Genomics and NuProbe, a genomics company that also operates in China. The company received a CE mark for its MRD test in April.

Last month, Carcinos reported that the American Academic Medical Center Mayo Clinic had a minority stake in the company for an undisclosed amount.

On the record

“At Carcinos, we are combining state-of-the-art oncology expertise with advances in technology and bioscience for early detection of cancer,” said Ramachandran Venkataraman, CEO and founder of Carcinos.

“Carcinos Healthcare to increase share in our vision [the] Access to distributed cancer monitoring and C2inform MRD testing will help us advance our commercialization efforts to bring it to labs across India, ”said Asaf Javiran, CEO and co-founder of C2i Genomics.

Leave a Reply

Your email address will not be published.